The primary concerns with this model include:
Restricted access to existing medicines: The 14 countries that the Centers for Medicare & Medicaid Services (CMS) has proposed referencing in this IPI model, on average, have access to only 48 percent of the new drugs developed in the past eight years, and it took an average of 16 months after their initial global launch for those drugs to become available in those 14 countries. If the United States adopts the prices of those countries, American patients may very well face the same access restrictions as exist in those countries and lose access to existing treatment options.
Give Working Families A Break
The Trump administration is using its regulatory authority to provide Americans more flexibility and choices of affordable health coverage, but it should take additional steps to help working families struggling with the cost of health coverage.
The administration has proposed allowing employers to establish defined contribution arrangements that enable their employees to purchase health insurance plans available outside the workplace.
But an important new option would be for an employee to use an HRA contribution to buy into their spouse’s plan at work.
Most of the real action on health reform is likely to happen in the regulatory space over the next two years, and the Trump administration can build on the opportunities it already has created with a regulatory fix that would increase access to health insurance for working families.
We submitted a comment letter on Friday recommending a change to the administration’s proposed rule that adds flexibility to Health Reimbursement Arrangements. We recommend the administration also allow funds from one spouse to be used to buy into group health coverage offered by the employer of the other working spouse.
About one-fourth of employees offered health insurance at work do not participate, generally because of cost. This change would increase uptake by allowing spouses to use funds deposited into an HRA account by one employer to obtain a family insurance policy offered by the other spouse’s employer.
President Trump was elected on his promise to stop other nations from taking advantage of the United States. Our allies let us pay for most of their own national defense needs. Treaties allowed once poor countries to hit American products with tariffs and trade barriers. The Paris agreement on climate change burdened our manufacturers and workers, while letting China and India build and expand without such onerous restrictions.
FDA Commissioner Scott Gottlieb blasted insulin makers Tuesday for what he called unacceptably high prices for a decades-old drug. And he rolled out a slate of new guidances for the industry he says will spur competition in the insulin market and bring down the drug’s cost when they take effect in 2020.
But in a speech at this week’s FDA/CMS Summit, Gottlieb stopped short of endorsing policies gaining steam on Capitol Hill that would dramatically change how insulin makers do business.
The Trump administration issued a proposed rule that would allow workers in large companies to use employee-provided tax-exempt health reimbursement arrangements (HRAs) to help pay premiums for individual health insurance.
The goal, according to administration officials, is to empower employees to make their own decisions regarding the health care they choose to purchase. Rules imposed under President Barack Obama prevented employers from covering medical costs tax-free via HRAs, declaring they would not meet the federal government’s mandate requiring companies with more than 50 full-time employees to provide health insurance covering all items the Obama administration deemed “essential.”
The Trump administration on Monday urged states to scale back their certificate-of-need laws and scope of practice rules, as the executive branch promised to push back against hospital consolidations. In a sweeping 120-page report encompassing more than 50 policy recommendations, the White House blamed government and commercial insurance for putting up barriers to patients and hurting price transparency.
The Trump administration has made important progress in loosening the federal government’s grip on private health insurance, freeing up more options for affordable health insurance. But the administration has veered off this free-market track with its recent proposal to, among other things, slap a form of imported price controls on a specific class of prescription drugs in Medicare.
Supporters of the nation’s health law condemn them. A few states, including California and New York, have banned them. Other states limit them.
But to some insurance brokers and consumers, short-term insurance plans are an enticing, low-cost alternative for healthy people.
HHS wants to cut down on the effort it takes providers to put information in electronic health records and to meet regulatory requirements, according to a new draft strategy. To achieve those goals, HHS, led by the CMS and the Office of the National Coordinator for Health Information Technology, recommended simplifying Quality Payment Program and Promoting Interoperability reporting requirements, standardizing clinical information in EHRs, and improving the user experience of software for better workflows.